Tisento Therapeutics — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
zagociguat 15mgPRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.	Accident vasculaire cérébral, Myopathies	Phase 2	À vérifier	United States, Australia, Germany, Italy, United Kingdom	À vérifier
zagociguat 30mgPRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.	Accident vasculaire cérébral, Myopathies	Phase 2	À vérifier	United States, Australia, Canada, Germany, Italy, United Kingdom	À vérifier
zagociguat 15mgPRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.	Accident vasculaire cérébral	Phase 2	À vérifier	United States, Australia, Canada, Germany, Italy, United Kingdom	À vérifier
zagociguat 15mgPRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.	Myopathies	Phase 2	À vérifier	United States, Australia, Germany, Italy, United Kingdom	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
zagociguat 15mg	Myopathies	Phase 2	NCT06961344	An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)	TERMINATED
zagociguat 15mg	Accident vasculaire cérébral	Phase 2	NCT06402123	PRIZM — A Phase 2b Study of Zagociguat in Patients With MELAS	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.